Search
CAR-T Cell Therapy Shows EFS Benefit in Pediatric Leukemia Subset
- OPACC
- Dec 19, 2024
- 1 min read
Treatment with bicistronic CD19/CD22 CAR-T cell therapy has shown event-free survival improvements in children with relapsed or refractory B-ALL.
Recent Posts
See AllDuring cancer treatment, children can face hurdles to maintaining healthy eating. Chemotherapy has many side effects, including loss of...
Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
Kommentare